Insights from nanomedicine into chloroquine efficacy against COVID-19
- PMID: 32203437
- PMCID: PMC7094976
- DOI: 10.1038/s41565-020-0674-9
Insights from nanomedicine into chloroquine efficacy against COVID-19
Abstract
Chloroquine — an approved malaria drug — is known in nanomedicine research for the investigation of nanoparticle uptake in cells, and may have potential for the treatment of COVID-19.
Conflict of interest statement
The authors declare no competing interests.
Figures
References
-
- Gao, J., Tian, Z. & Yang, X. Biosci. Trends10.5582/bst.2020.01047 (2020).
Publication types
MeSH terms
Substances
Grants and funding
- R21AI52318/U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)/International
- R21EB026347/U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB)/International
- DODW8IXWH1910926/U.S. Department of Defense (United States Department of Defense)/International
- R21 EB026347/EB/NIBIB NIH HHS/United States
- R01AI113725/U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)/International
- R01 AI113725/AI/NIAID NIH HHS/United States
- R01 HD090927/HD/NICHD NIH HHS/United States
- R01AI122932/U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)/International
- R21 AI152318/AI/NIAID NIH HHS/United States
- R01 AI122932/AI/NIAID NIH HHS/United States
- R21AI126361/U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)/International
- R21 AI126361/AI/NIAID NIH HHS/United States
- R01HD090927/U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)/International
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical